Springer Science and Business Media LLC
Cure8 research brief
Why This Matters
Patients and clinicians exploring new, less-invasive options for fibrostenotic colonic Crohn's disease may be interested because this study reports that intralesional PRP after balloon dilation is feasible and appears safe, but restenosis remained common.
Who Should Pay Attention
Adult patients with colonic Crohn's disease strictures, gastroenterologists who perform endoscopic dilation, and researchers designing trials of endoscopic adjuncts for fibrostenotic IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This was a prospective, single-arm pilot trial reporting feasibility and safety of endoscopic intralesional PRP after EBD for colonic CD strictures. PRP injections (1–2 mL at several points) were given into the dilated segment after balloon dilation. The study found no adverse events directly attributed to PRP.
Two delayed hemorrhages were linked to concurrent polypectomy and one perforation occurred from balloon dilation (managed endoscopically). Restenosis—defined as inability to pass a 10.5-mm scope—occurred in nearly half of patients by 3 weeks and in most patients by 1 year, and intestinal ultrasound measurements did not show meaningful improvement.
Because this is a small, single-arm pilot with no control group, it cannot establish whether PRP helps prevent restenosis; its main contribution is a safety signal and benchmark restenosis rates to guide future research.
Keep In Mind
This is a small, single-arm pilot (29 patients) reported as an abstract/full-text on Research Square (posted-content) with structured-content depth labeled as an abstract. It sets a safety benchmark but cannot demonstrate efficacy without a controlled trial or larger studies with repeat dosing or comparator arms.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationSpringer Science and Business Media LLC
AuthorsYi Lu, Tao Yang, Jing Li +10 more
Study typePosted Content
Indexed viaCrossref
Source typeResearch paper
PublishedOct 11, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Evolving role of intestinal ultrasound in the evaluation of Crohn's disease: A clinical- radiological perspective
Intestinal ultrasound is increasingly used to evaluate Crohn’s disease because it’s noninvasive, repeatable, and can detect activity and some complications—potentially reducing reliance on more invasive tests. Wider...
Intestinal Ultrasound Plus Fecal Calprotectin Predicts Crohn's Recurrence | Docwire News
Noninvasive tests at 3 months after ileocecal resection (ultrasound + fecal calprotectin) may identify patients at high risk of endoscopic recurrence by 6 months. That could help avoid or target postoperative endoscopy...
Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort.
Adding partial enteral nutrition to ustekinumab was associated with better clinical, endoscopic, radiologic, and nutritional outcomes at 52 weeks in this multicentre real-world cohort of Crohn’s disease patients. This...